InMed Pharmaceuticals Inc. reported on April 21, 2026, that they amended two agreements with Sabby and H.C. Wainwright affiliates, lowering the exercise price for shares from $2.436 to $0.80 for Sabby, and similar reductions for Wainwright's options. This is a significant event as it impacts the company's capital structure.